Daiichi-Sankyo

LONDON, November 22, 2011 - Sevikar HCT▼ combines three treatments in one reducing the number of tablets patients take to manage high blood pressure Today Daiichi Sankyo UK announces that it has launched Sevikar HCT, the first three-in-one pill in the UK to treat high blood pressure.[1] This condition affects around 8.5 million people in the UK.[2] High blood pressure, or hypertension, is known as the 'silent killer' as it rarely has obvious symptoms.[3] Left untreated or uncontrolled, it is the biggest cause of stroke.[4] To view the Multimedia News Release, please click: www.multivu.com/pages/52788-daiichi-sankyo Almost 2 million people in the UK take three or more pills for their high blood pressure,[2] however up to 80% of patients don't take their medication as directed by their doctor,[5] or end up throwing them away.

MUNICH, July 8, 2011 - For distribution to consumer and medical media - Findings From the Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Suggest the Need to Implement a Consistent Strategy to Improve and Maintain Blood Pressure Control Physicians' treatment approaches to hypertension management are inconsistent[1] despite ESH-ESC (European Society of Hypertension and European Society of Cardiology) arterial hypertension guidelines[2], which could put patients with elevated blood pressure at risk, according to findings published recently in the Journal of Hypertension.[1] This inconsistency in adherence to the guidelines amongst physicians is one of the contributing factors to the substantial health and economic burden associated with uncontrolled blood pressure across Europe.[1] Hypertension causes 7.6 million premature deaths worldwide and as many as 1 billion people may have uncontrolled hypertension worldwide.[3,4] If left untreated, hypertension may lead to serious cardiovascular health complications such as heart attack or stroke.[5] Uncontrolled hypertension is therefore a significant contributor to healthcare spending across Europe as the annual cardiovascular health bill in the EU is in excess of €190 billion.[6] The Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey sought the views of 2629 physicians from primary and secondary care around Europe and forms part of HypertensionCare, a commitment from Daiichi Sankyo to providing increased knowledge and insight to physicians across Europe.

MUNICH, April 18, 2011 - Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib (ARQ 197).

TOKYO and WOBURN, Massachusetts, January 12, 2011 - Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc.

MUNICH, December 20, 2010 - Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP).